1. 首頁 > 健康養生 > >

癌癥|《自然·癌癥》：發現了能重塑“癌王”腫瘤微環境的聯合療法( 四 )

治療療法腫瘤曲美替尼曲美尼達尼布亞型T細胞充質癌癥癌細胞Saur


癌癥|《自然·癌癥》：發現了能重塑“癌王”腫瘤微環境的聯合療法
文章圖片

參考文獻：
[1] Quaresma M, Coleman M P, Rachet B. 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study[J]. Lancet, 2015, 385(9974): 1206-18.
[2] Aung K L, Fischer S E, Denroche R E, et al. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial[J]. Clin Cancer Res, 2018, 24(6): 1344-1354.
[3] S N K, Wilson G W, Grant R C, et al. Morphological classification of pancreatic ductal adenocarcinoma that predicts molecular subtypes and correlates with clinical outcome[J]. Gut, 2020, 69(2): 317-328.
[4] Morrison A H, Byrne K T, Vonderheide R H. Immunotherapy and Prevention of Pancreatic Cancer[J]. Trends Cancer, 2018, 4(6): 418-428.
[5] Balachandran V P, ?uksza M, Zhao J N, et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer[J]. Nature, 2017, 551(7681): 512-516.
[6] Chen D S, Mellman I. Elements of cancer immunity and the cancer–immune set point[J]. Nature, 2017, 541(7637): 321-330.
[7] Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer[J]. Br J Cancer, 2013, 108(4): 914-23.
[8] Falcomatà C, B?rthel S, Widholz S A, et al. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment[J]. Nature Cancer, 2022.
[9] Mueller S, Engleitner T, Maresch R, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes[J]. Nature, 2018, 554(7690): 62-68.